Status:
SUSPENDED
Laryngeal Allograft Transplantation
Lead Sponsor:
Mayo Clinic
Conditions:
Larynx Stenosis
Larynx Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this proposed study is to obtain safety and efficacy data on human laryngeal allograft transplantation in an effort to safely use these procedures as a viable reconstructive option for ...
Detailed Description
Patients with severe laryngeal or laryngotracheal incompetence without other reconstructive options will be considered for cadaveric laryngotracheal transplantation. Data will be collected from 10 pat...
Eligibility Criteria
Inclusion
- Potential subjects for this study include patients with severe laryngeal dysfunction or a previous laryngectomy. For the purposes of this study, severe laryngeal dysfunction is defined as the loss of normal laryngeal function resulting in significant dysphonia, dysphagia, or dyspnea.
- Ages 18 years and older
- Male or Female
- One of the following:
- Severe laryngeal dysfunction as described above
- Laryngeal stenosis
- 5 years or longer s/p definitive management for head and neck cancer
- Laryngeal cancer requiring total laryngectomy in a patient already on immunosuppression
- Low-grade chondrosarcoma requiring total laryngectomy
- Ability to obtain informed consent from the patient
Exclusion
- Poor surgical candidacy secondary to poor physical/mental health as determined by a pre-operative medical evaluation
- General medical status
- Pregnancy
- Any systemic disease which would alter life expectancy
- Active neoplastic disease, not considered yet to be cured (Exceptional cases will be considered in case by case discussion)Less than 5 years s/p definitive management for cancer
- Cancer within the last 5 years (Exceptional cases will be considered in case by case discussion)
- Obesity (Body Mass Index \>29 - 30)(Exceptional cases will be considered on a case by case basis)
- Cachexia (BMI\<18)(Exceptional cases will be considered on a case by case basis) Significant renal dysfunction (Creatinine clearance \< 50 ml/min.)
- Significant hepatic dysfunction
- Significant kidney damage
- Unmanageable infections
- Unable to participate in preoperative exercise training
- Unable to be weaned to equal or less than 10 mg/day of steroids
- Untreatable cardiac disease
- Active neuromuscular disease
- History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux
- Patients with active connective tissue diseases (exceptions to be considered in a case by case basis)
- Patients unable to achieve \> 600 feet in a 6 minute walk test (exceptions to be considered in a case by case basis)
- Patients considered having active immunodeficiency disorders (exceptions to be considered in a case by case basis)
- Multiple co-morbidities that would make transplantation prohibitively risky
- Psychosocial parameters
- Severe mental retardation, psychosis, depression or organic brain syndrome
- Uncontrolled diabetes mellitus. Once HbA1C \< 7, reevaluate for candidacy.
- Active substance use within 6 months
- Active smoking within 6 months
- Active alcoholism within 6 months
- Inability to comply with transplant-related management and medical follow-up
- Any other circumstances that deem the candidate high risk from a psychosocial perspective
Key Trial Info
Start Date :
May 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2033
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03269396
Start Date
May 19 2023
End Date
May 1 2033
Last Update
September 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Phoenix, Arizona, United States, 85054